News & Updates
Filter by Specialty:
Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
The risk stratification criteria used in the CHAARTED and LATITUDE trials can accurately assess prognosis in patients with castration-resistant prostate cancer (CRPC), but are insufficient to differentiate between the therapeutic outcomes of androgen receptor pathway inhibitors (ARPI) and docetaxel, a new study has found.
Risk stratification criteria show good prognostic value in CRPC, but not enough to guide treatment
24 Jan 2022
PSA mRNA in circulating tumour cells a potential new biomarker for prostate cancer progression
Levels of prostate specific antigen (PSA) mRNA in circulating tumour cells can be used alongside serum PSA protein levels to refine the assessment of disease progression in patient with metastatic castration-resistant prostate cancer (mCRPC), a new study has found.
PSA mRNA in circulating tumour cells a potential new biomarker for prostate cancer progression
23 Jan 2022
Sitafloxacin a promising treatment alternative for UTI
Oral sitafloxacin was just as effective and safe as levofloxacin for the treatment of complicated and uncomplicated urinary tract infections (UTIs) in adults, according to a phase III study from China.
Sitafloxacin a promising treatment alternative for UTI
20 Jan 2022
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
In patients with clinically localized Gleason 9–10 prostate cancer, dose-escalated radiotherapy confers better biochemical disease-free survival and prostate cancer-specific mortality than conventional doses, a recent study has found.
High-dose radiotherapy boosts biochemical control in Gleason 9–10 prostate cancer
15 Jan 2022
What is the ideal number of NACT cycles for muscle invasive bladder cancer?
Four cycles of neoadjuvant chemotherapy (NACT) results in better pathological response and survival than three NACT cycles in patients with muscle invasive bladder cancer, reveals a recent study.
What is the ideal number of NACT cycles for muscle invasive bladder cancer?
06 Jan 2022
Robotic-assisted radical cystectomy for bladder cancer: Intracorporeal urinary diversion of benefit
Intracorporeal urinary diversion (ICUD) is associated with similar postoperative complication rates, reduced blood loss and shorter hospitalization vs extracorporeal urinary diversion (ECUD) in patients undergoing robotic-assisted radical cystectomy (RARC) for localized bladder cancer, data from the Asian RARC Consortium registry have shown.
